Top

Acta Epileptologica

Published in:

Open Access 01-12-2024 | Epilepsy | Case Report

Improvement of epilepsy secondary to acquired immunodeficiency syndrome with intestinal microbiota preparations: a case report

Authors: Chuhui Lin, Ting Zeng, Yuhong Deng

Published in: Acta Epileptologica | Issue 1/2024

Abstract

Background

Epilepsy secondary to acquired immunodeficiency syndrome (AIDS) can be challenging to manage. The potential interactions between antiretroviral drugs and antiepileptic drugs may result in the failure of both treatments. Therefore, it is crucial to develop more effective strategies to enhance the clinical outcomes of patients.

Case presentation

We report a case of epilepsy secondary to AIDS. After administration of Bacteroides Fragilis 839 (BF839), the secondary generalized tonic-clonic seizures disappeared, the frequency of complex partial seizures decreased by 70%, and the duration of each episode was shortened. Additionally, long-term diarrhea associated with antiretroviral therapy for AIDS resolved, and the syphilis serofast reaction turned negative. No serious adverse reactions were observed during the three-year follow up.

Conclusions

This case report suggests that the specific gut microbiota preparation could possibly improve refractory epilepsy in HIV patients while also potentially alleviating adverse reactions to antiretroviral drugs and concurrent syphilis infection. Our case may provide a new perspective for the treatment of HIV infection/AIDS.

Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): Systematic review and meta-analysis. Epilepsy Behav. 2019;93:49–55.CrossRefPubMed

Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George J, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78(2):139–45.CrossRefPubMedPubMedCentral

Zhang JJ, Yu LX, Xu LZ, Wang WY, Zhang HJ, Pan ZH, et al. Isolation and identification of a non-toxic and fragile Bacteroid strain. Ningxia Med J. 1991;13:216–8.

Zhang JJ, Zhang HM, Zhang Y, Zhang HG, Bi L, Zhang XC, et al. Clinical application study of Bacteroides fragilis (BF839) bacterial solution. Chin J Biol Prod. 1995;8:63–5.

Feng SZ, Zhang HP. Research progress on Bacteroides fragilis. Microbiol Bull. 2015;42:1366–71.

Deng YH, Lin CH, Cao DZ. The beneficial effect of Bacteroides fragilis (BF839) as a supplementary treatment in drug-resistant epilepsy: a pilot study. Epilepsy. 2021;7:288–95.

Lin CH, Zeng T, Wu QY, Cao DZ, Li BM, Deng YH. Efficacy of bacteroides fragilis 839 in the treatment of newly diagnosed “probable autoimmune-related epilepsy.” Epilepsy. 2022;8:298–304.

Carter GM, Esmaeili A, Shah H, Indyk D, Johnson MS, Andreae MH, et al. Probiotics in human immunodeficiency virus infection: a systematic review and evidence synthesis of benefits and risks. Open Forum Infect Dis. 2016;3(4):ofw164.CrossRefPubMedPubMedCentral

Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS. 2016;30(18):2737–51.CrossRefPubMed

10.

McHardy IH, Li X, Tong M, Ruegger P, Jacobs JP, Borneman J, et al. HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome. 2013;1(1):26.CrossRefPubMedPubMedCentral

11.

Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth CB, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10(2):e1003829.CrossRefPubMedPubMedCentral

12.

Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrús ML, Madrid N, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015;8(4):760–72.CrossRefPubMed

13.

Vujkovic-Cvijin I, Somsouk M. HIV and the gut microbiota: composition, consequences, and avenues for amelioration. Curr HIV/AIDS Rep. 2019;16(3):204–13.CrossRefPubMedPubMedCentral

14.

Dillon SM, Kibbie J, Lee EJ, Guo K, Santiago ML, Austin GL, et al. Low incidence of colonic butyrate producing bacteria in HIV infection is associated with microbial translation and immune activation. AIDS. 2017;31(4):511–21.CrossRefPubMed

15.

Lu J, Ma SS, Zhang WY, Duan JP. Changes in peripheral blood inflammatory factors (TNF-α and IL-6) and intestinal flora in AIDS and HIV-positive individuals. J Zhejiang Univ Sci B. 2019;20(10):793–802.CrossRefPubMedPubMedCentral

16.

Ling N, Zhang X, Forsythe S, Zhang D, Shen Y, Zhang J, et al. Bacteroides fragilis ameliorates Cronobacter malonaticus lipopolysaccharide-induced pathological injury through modulation of the intestinal microbiota. Front Immunol. 2022;13:931871.CrossRefPubMedPubMedCentral

17.

Round JL, Mazmanian SK. Industriable Foxp3+regulatory T-cell development by a commercial bacterium of the internal microbiota. Proc Natl Acad Sci U S A. 2010;107(27):12204–9.CrossRefPubMedPubMedCentral

18.

Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620–5.CrossRefPubMed

19.

Jiancheng Z. The effect of combined treatment with benzylpenicillin and thymopentin on immune function and TRUST negative conversion rate in patients with early syphilis serum fixation. Chin Foreign Med Res. 2022;20(25):13–6.

20.

Agmon-Levin N, Elbirt D, Asher I, Gradestein S, Werner B, Sthoeger Z. Syphilis and HIV co-infection in an Israeli HIV clinic: incidence and outcome. Int J STD AIDS. 2010;21(4):249–52.CrossRefPubMed

21.

Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes. 2014;5(4):562–70.CrossRefPubMed

22.

Noguera-Julian M, Rocafort M, Guillén Y, Rivera J, Casadellà M, Nowak P, et al. Gut microbiota linked to sexual preference and HIV infection. EBioMedicine. 2016;5:135–46.CrossRefPubMedPubMedCentral

Title: Improvement of epilepsy secondary to acquired immunodeficiency syndrome with intestinal microbiota preparations: a case report
Authors: Chuhui Lin
Ting Zeng
Yuhong Deng
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Epilepsy
Syphilis
Acquired Immune Deficiency Syndrome
Respiratory Microbiota
Human Immunodeficiency Virus
Immunodeficiency
Focal Seizure
Published in: Acta Epileptologica / Issue 1/2024
Print ISSN: 2096-9384
Electronic ISSN: 2524-4434
DOI: https://doi.org/10.1186/s42494-024-00156-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improvement of epilepsy secondary to acquired immunodeficiency syndrome with intestinal microbiota preparations: a case report

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

A survey of ictal physical examination during VEEG monitoring in a tertiary epilepsy center

Research progress on the electrophysiological indicators to predict the efficacy of vagus nerve stimulation for drug-refractory epilepsy

Effects of stigma on the quality of life in patients with epilepsy

Correction: Biomolecular mechanisms of epileptic seizures and epilepsy: a review

Impact of prenatal, neonatal, and postnatal factors on epilepsy risk in children and adolescents: a systematic review and meta-analysis

Clinical characteristics and impact of comorbidities on the prognosis of senile epilepsy in Southwest China: a retrospective cohort study